Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_27997
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
UNIL/CHUV
Titre
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Périodique
Journal of Clinical Oncology
Auteur⸱e⸱s
Smith J.W., Walker E.B., Fox B.A., Haley D., Wisner K.P., Doran T., Fisher B., Justice L., Wood W., Vetto J., Maecker H., Dols A., Meijer S., Hu H.M., Romero P., Alvord W.G., Urba W.J.
ISSN
0732-183X (Print)
ISSN-L
0732-183X
Statut éditorial
Publié
Date de publication
2003
Volume
21
Numéro
8
Pages
1562-1573
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
Publication Status: ppublish
Mots-clé
Adult, Aged, Aged, 80 and over, CD8-Positive T-Lymphocytes/immunology, Cancer Vaccines/administration &amp, dosage, Female, Flow Cytometry, Fluorescence, Freund's Adjuvant/administration &amp, dosage, HLA-A2 Antigen/analysis, Humans, Interferon-gamma/metabolism, Leukapheresis, Male, Melanoma/immunology, Membrane Glycoproteins/administration &amp, dosage, Membrane Glycoproteins/adverse effects, Middle Aged, Neoplasm Proteins/administration &amp, dosage, Neoplasm Proteins/adverse effects, Peptides, Pilot Projects, Skin Neoplasms/immunology, Treatment Outcome, gp100 Melanoma Antigen
OAI-PMH
oai:serval.unil.ch:BIB_27997
DOI
10.1200/JCO.2003.09.020
Pubmed
12697882
Web of science
000182300200022
Création de la notice
19/11/2007 13:24
Dernière modification de la notice
20/08/2019 14:06
Données d'usage